BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11477584)

  • 1. EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain.
    Maeda A; Kiss C; Chen F; Ehlin-Henriksson B; Nagy N; Szekely L; Takada K; Klein E; Klein G
    Int J Cancer; 2001 Sep; 93(5):714-9. PubMed ID: 11477584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.
    Trivedi P; Spinsanti P; Cuomo L; Volpe M; Takada K; Frati L; Faggioni A
    J Virol; 2001 May; 75(10):4929-35. PubMed ID: 11312367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
    Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
    Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
    Hutchings IA; Tierney RJ; Kelly GL; Stylianou J; Rickinson AB; Bell AI
    J Virol; 2006 Nov; 80(21):10700-11. PubMed ID: 16920819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis.
    Kelly GL; Milner AE; Tierney RJ; Croom-Carter DS; Altmann M; Hammerschmidt W; Bell AI; Rickinson AB
    J Virol; 2005 Aug; 79(16):10709-17. PubMed ID: 16051863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines.
    Nakagomi H; Dolcetti R; Bejarano MT; Pisa P; Kiessling R; Masucci MG
    Int J Cancer; 1994 Apr; 57(2):240-4. PubMed ID: 8157362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.
    Schaefer BC; Strominger JL; Speck SH
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10565-9. PubMed ID: 7479841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
    Komano J; Sugiura M; Takada K
    J Virol; 1998 Nov; 72(11):9150-6. PubMed ID: 9765461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes.
    Finke J; Fritzen R; Ternes P; Trivedi P; Bross KJ; Lange W; Mertelsmann R; Dölken G
    Blood; 1992 Jul; 80(2):459-69. PubMed ID: 1378321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus.
    Rooney C; Howe JG; Speck SH; Miller G
    J Virol; 1989 Apr; 63(4):1531-9. PubMed ID: 2538644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael.
    Masucci MG; Contreras-Salazar B; Ragnar E; Falk K; Minarovits J; Ernberg I; Klein G
    J Virol; 1989 Jul; 63(7):3135-41. PubMed ID: 2470924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.
    Kelly GL; Long HM; Stylianou J; Thomas WA; Leese A; Bell AI; Bornkamm GW; Mautner J; Rickinson AB; Rowe M
    PLoS Pathog; 2009 Mar; 5(3):e1000341. PubMed ID: 19283066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.
    Nanbo A; Inoue K; Adachi-Takasawa K; Takada K
    EMBO J; 2002 Mar; 21(5):954-65. PubMed ID: 11867523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
    Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    Gregory CD; Rowe M; Rickinson AB
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle.
    Evans TJ; Jacquemin MG; Farrell PJ
    Virology; 1995 Feb; 206(2):866-77. PubMed ID: 7856099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage.
    Kerr BM; Lear AL; Rowe M; Croom-Carter D; Young LS; Rookes SM; Gallimore PH; Rickinson AB
    Virology; 1992 Mar; 187(1):189-201. PubMed ID: 1310556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.
    Murray RJ; Young LS; Calender A; Gregory CD; Rowe M; Lenoir GM; Rickinson AB
    J Virol; 1988 Mar; 62(3):894-901. PubMed ID: 2828684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.